Edition:
United Kingdom

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

0.82USD
19 Oct 2018
Change (% chg)

$-0.12 (-12.23%)
Prev Close
$0.94
Open
$0.95
Day's High
$0.95
Day's Low
$0.75
Volume
25,901
Avg. Vol
19,311
52-wk High
$3.09
52-wk Low
$0.75

Latest Key Developments (Source: Significant Developments)

Neuralstem Announces NSI-189 Granted Orphan Drug Designation From The U.S. FDA
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Neuralstem Inc ::NEURALSTEM ANNOUNCES NSI-189 GRANTED ORPHAN DRUG DESIGNATION FROM THE U.S. FDA FOR THE TREATMENT OF ANGELMAN SYNDROME.  Full Article

Neuralstem Q1 Loss Per Share $0.14
Tuesday, 15 May 2018 

May 15 (Reuters) - Neuralstem Inc ::NEURALSTEM PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FISCAL RESULTS.Q1 LOSS PER SHARE $0.14.CASH AND INVESTMENTS WAS $9.7 MILLION AT MARCH 31, 2018 AS COMPARED TO $11.7 MILLION AT DECEMBER 31, 2017.NEURALSTEM - EXPECTS EXISTING CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS TO FUND OPSS BASED ON CURRENT PLANS, INTO Q1 2019.  Full Article

Neuralstem Q3 loss per share $0.01
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Neuralstem Inc :Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update.Q3 loss per share $0.01.Neuralstem - ‍expect to provide detailed update on corporate strategy after post-phase 2 meeting with fda in h1 2018​.Neuralstem Inc - ‍ recent financing further extended co's cash runway to sufficiently support continued research on NSI-189 and to support operations​.Neuralstem Inc - ‍plans to meet with U.S. Food and Drug Administration in first half of 2018 to discuss clinical development path for NSI-189​.  Full Article